HMB-002: a monovalent antibody that elevates circulating VWF and FVIII levels for treatment of von Willebrand disease.

At arterial shear rates, only a nonsignificant trend toward reduced cumulative capture was observed at 500 s −1 (22% lower, P = .06), whereas no detectable difference occurred at 250 s −1 ( Figure 3 J); importantly, final platelet adhesion levels were normal after 10 minutes at both shear rates.

also in 5,406 other papers

Similarly, HMB-002 surrogate treatment in a type 1 VWD mouse model showed a trend toward improved hemostasis, with bleeding times not significantly different from hemostatically normal controls, further supporting retained functionality of HMB-002–bound VWF.

also in 53,322 other papers